ContraFect Corp.(NASDAQ : CFRX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||4.81%||6.44||0.7%||$450.18m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.72%||561.59||2.7%||$438.99m|
|GILD||Gilead Sciences, Inc.||0.29%||67.10||1.0%||$414.29m|
|XLRN||Acceleron Pharma, Inc.||-0.56%||172.76||5.3%||$348.35m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.45%||186.24||1.9%||$270.97m|
|XENE||Xenon Pharmaceuticals, Inc.||2.21%||30.47||0.4%||$163.92m|
|CRSP||CRISPR Therapeutics AG||-1.64%||98.61||0.6%||$159.45m|
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.